Free delivery options available over £29*

Eradia Metronidazole Liquid for Dogs

Eradia Metronidazole Liquid for Dogs
30ml Bottle

Images are for illustration purposes only. Packaging may change from time to time and images on our website may or may not be updated.

  • 30ml Bottle £10.49
  • 100ml Bottle £20.99

Selection of 2 products from

£10.49 to £20.99

Description

Eradia Metronidazole Liquid for Dogs

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm (Collections only)
  • Email: [email protected]

All prices include VAT where applicable.

Medication Datasheets

100ml Bottle

ERADIA 125 mg/mL oral suspension for dogs

Qualitative and quantitative composition

Each mL contains

Active substance:

Metronidazole 125 mg

Excipients:

Butylhydroxytoluene (E321) 0.2 mg

Pharmaceutical form

Oral suspension.

Flavoured oily suspension with brown visible particles.

Clinical particulars

Dogs

Treatment of infections of the gastrointestinal tract caused by Giardia spp. and Clostridium spp. (i.e. C. perfringens or C. difficile).

Treatment of infections of the urogenital tract, oral cavity, throat and skin caused by obligate anaerobic bacteria (e.g. Clostridium spp.) susceptible to metronidazole.

Contraindications

Do not use in case of hepatic disorders.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

None.

Special precautions for use in animals

Due to the likely variability (time, geographical) in the occurrence of metronidazole resistant bacteria, bacteriological sampling and susceptibility testing are recommended.

Whenever possible, the product should only be used based on susceptibility testing.

Official, national and regional antimicrobial policies should be taken into account when the veterinary medicinal product is used.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Metronidazole has confirmed mutagenic and genotoxic properties in laboratory animals as well as in humans. Metronidazole is a confirmed carcinogen in laboratory animals and thus may have carcinogenic effects in humans as well. However, there is inadequate evidence in humans for the carcinogenicity of metronidazole.

The product can cause skin sensitisation. In case of known hypersensitivity to metronidazole or other nitroimidazole derivatives or one of the components of the product, avoid contact with the veterinary medicinal product.

Avoid contact with the skin or mucous membranes including hand-to-mouth contact.

To avoid such contact wear impervious gloves when handling the product and/or for direct administration into the animal's mouth.

Do not allow treated dogs to lick persons immediately after intake of the medication.

Wash hands after use.

In case of skin contact, wash thoroughly the affected area.

Metronidazole may cause adverse (neurological) effects.

Avoid accidental ingestion.

Do not drink, eat or smoke when administering the product.

Close the bottle immediately after use to avoid the child gaining access to the contents. Do not leave a syringe containing solution in the sight or reach of children. In order to prevent children from getting access to used syringes, keep the syringes in the original packaging after use.

In case of accidental ingestion, seek-medical advice immediately and show the package leaflet or the label to physician.

Additional warnings when administering the product into the feed:

Avoid the access of children to the dog’s medicated food. In order to prevent children from getting access to the dog’s medicated food, pour it over a part of the feed and wait until the animal has completely consumed the medicated feed, then administer the rest of the feed. Give the treatment out of the sight and reach of children. Any uneaten medicated food must be removed immediately and the bowl washed thoroughly; wear gloves and wash hands when handling the product and cleaning the contaminated food bowl.

The following adverse reactions may occur after administration of metronidazole: vomiting, hepatotoxicity and neutropenia. In very rare cases, neurological signs may occur especially after prolonged treatment with metronidazole.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Studies in laboratory animals have shown inconsistent results with regard to teratogenic/embryotoxic effects of metronidazole. Therefore, use of this product during pregnancy is not recommended. Metronidazole is excreted in milk and use during lactation is therefore not recommended.

Metronidazole may have an inhibitory effect on the degradation of other drugs in the liver, such as phenytoin, cyclosporine and warfarin.

Cimetidine may decrease the hepatic metabolism of metronidazole resulting in increased serum concentration of metronidazole.

Phenobarbital may increase hepatic metabolism of metronidazole resulting in decreased serum concentration of metronidazole.

Amounts to be administered and administration route

Oral use.

The recommended dose is 50 mg metronidazole per kg bodyweight per day (i.e. 0.4 mL per kg bodyweight), preferably given in two equally divided doses (i.e. 25 mg equivalent to 0.2 mL per kg bodyweight twice daily) for 5-7 days.

To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing and overdosing.

The dosage table is intended as a guide to dispensing the product at the volume corresponding to either 25 mg/kg for administration twice daily or 50 mg/kg for administration once daily.Examples of bodyweight (kg)Volume toadministertwice dailyfor 25mg/kgVolume toadministeronce dailyfor 50mg/kg10.4ml20.4ml0.8ml30.6ml1.2ml40.8ml1.6ml51.0ml2.0ml102.0ml4.0ml153.0ml6.0ml204.0ml8.0ml255.0ml10.0ml306.0ml12.0ml357.0ml14.0ml408.0ml16.0ml

Examples of bodyweight (kg)

Volume to

administer

twice daily

for 25mg/kg

Volume to

administer

once daily

for 50mg/kg

For doses requiring more than two filled syringes, the dosing should be twice daily in order to minimize counting and dosing errors.

The oral suspension is delivered through the package described below:

A - Shake the bottle vigorously before use.

B - Unscrew the protective overcap.

C - Insert the syringe into the upper white part of the cap (finger-grip) by pushing firmly, then, while pushing, turn the syringe to the right (clockwise) until the green smile appears.

D - Turn the bottle upside down and withdraw the prescribed volume of the product, in the upside down position.

E - Once the correct volume of the product has been drawn into the syringe, unscrew the syringe from the cap without pushing by turning it to the left (counterclockwise) until the red smile appears again, then continue to turn in order to unfasten the syringe.

The system can also be closed by turning the finger-grip manually.

F - Screw the protective overcap back on.

Administer the product by pouring it over a part of the feed or by direct administration into the animal's mouth. Wear impervious gloves when handling the product and/or administering the product into the animal's mouth.

When administered over the feed, wait until the animal has completely consumed the medicated feed, then administer the rest of the feed.

Adverse events are more likely to occur at doses and treatment durations in excess of the recommended treatment regimen. If neurological signs occur, treatment should be discontinued and the patient should be treated symptomatically.

Not applicable.

Pharmacological particulars

Pharmacotherapeutic group: Agent against protozoal disease, nitroimidazole derivative.

ATCvet code: QP51AA01.

Pharmacodynamic properties

After metronidazole has penetrated the bacteria the molecule is reduced by the sensitive bacteria (anaerobe). The metabolites that are created have a toxic effect on the bacteria through binding to the bacterial DNA. In general metronidazole is bactericidal for sensitive bacteria in concentrations equal to or a little higher than the minimum inhibiting concentration (MIC).

Minimum Inhibitory Concentrations (MICs) have been determined for metronidazole in European isolates of target bacteria, isolated from dogs with gastrointestinal disease in 2016.SpeciesMIC range (μg/ml)MIC50 (μg/ml)MIC90 (μg/ml)Clostridium spp.(C.difficile & C.perfringens)0.5 - 211

Species

MIC range (μg/ml)

MIC50 (μg/ml)

MIC90 (μg/ml)

The MICs of the collected pathogens showed mono-modal distribution profiles with good susceptibility towards metronidazole. Clinical breakpoints* for metronidazole are established for anaerobes: susceptible: ≤8 µg/ml; intermediate: 16 µg/ml; resistant: ≥32 µg/ml.

According to these breakpoints no clinical resistant strains of Clostridium spp. pathogens were observed.

*(CLSI, 2017. Performance Standards for Antimicrobial Susceptibility Testing -Twenty-Seventh Edition M100. Clinical and Laboratory Standards Institute (CLSI), Wayne, PA 19087-1898 USA)

Clinically metronidazole does not have any relevant effect on facultative anaerobe, obligate aerobe and microaerophilic bacteria.

Metronidazole is also active in protozoa. In Giardia spp. in particular, metronidazole primarily targets the trophozoites (active replication of the parasite) resulting in their death and by consequence leading to dramatic decrease in cyst shedding.

After administration of the higher dose (50 mg/day/kg of bw), the absolute bioavailability is 98 % in fasted dog. The mean maximum concentration (Cmax) was 62.4 µg/mL +/- 9.7 (mean +/- SD) in plasma and occurs between 0.25 and 4 hours after dosing (Tmax). Food was shown to decrease the oral bioavailability which remains high in fed dogs with relative F of 81% (with F fasted = 100%). Metronidazole penetrates into the tissues and bodily fluids, such as saliva, milk, vaginal secretions and semen. Metronidazole is metabolised in the liver, by side chain oxidation and glucuronide synthesis. Both metabolites and unchanged drug are eliminated in the urine (mostly) and faeces. Elimination half-life is between 3 to 5 hours.

Pharmaceutical particulars

Butylhydroxytoluene (E321)

Aluminium stearate

Stearic acid (E570)

Poultry liver powder

Triglycerides medium chain

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the immediate packaging:

- 30 ml bottle: 3 months.

- 100 ml bottle: 6 months.

Store below 30° C.

Opaque white polyethylene terephthalate bottle closed with a plastic dispenser cap.

Carton box containing a 30 ml or 100 ml bottle and a 3 ml graduated syringe.

Not all pack sizes may be marketed

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Marketing Authorisation Holder (if different from distributor)

VIRBAC

1ère avenue – 2065m – LID

06516 Carros

France

Marketing Authorisation Number

Vm 05653/4210

Date of the first authorisation or date of renewal

10 April 2018

Date of revision of the text

April 2018

Any other information

Legal category

30ml Bottle

ERADIA 125 mg/mL oral suspension for dogs

Qualitative and quantitative composition

Each mL contains

Active substance:

Metronidazole 125 mg

Excipients:

Butylhydroxytoluene (E321) 0.2 mg

Pharmaceutical form

Oral suspension.

Flavoured oily suspension with brown visible particles.

Clinical particulars

Dogs

Treatment of infections of the gastrointestinal tract caused by Giardia spp. and Clostridium spp. (i.e. C. perfringens or C. difficile).

Treatment of infections of the urogenital tract, oral cavity, throat and skin caused by obligate anaerobic bacteria (e.g. Clostridium spp.) susceptible to metronidazole.

Contraindications

Do not use in case of hepatic disorders.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

None.

Special precautions for use in animals

Due to the likely variability (time, geographical) in the occurrence of metronidazole resistant bacteria, bacteriological sampling and susceptibility testing are recommended.

Whenever possible, the product should only be used based on susceptibility testing.

Official, national and regional antimicrobial policies should be taken into account when the veterinary medicinal product is used.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Metronidazole has confirmed mutagenic and genotoxic properties in laboratory animals as well as in humans. Metronidazole is a confirmed carcinogen in laboratory animals and thus may have carcinogenic effects in humans as well. However, there is inadequate evidence in humans for the carcinogenicity of metronidazole.

The product can cause skin sensitisation. In case of known hypersensitivity to metronidazole or other nitroimidazole derivatives or one of the components of the product, avoid contact with the veterinary medicinal product.

Avoid contact with the skin or mucous membranes including hand-to-mouth contact.

To avoid such contact wear impervious gloves when handling the product and/or for direct administration into the animal's mouth.

Do not allow treated dogs to lick persons immediately after intake of the medication.

Wash hands after use.

In case of skin contact, wash thoroughly the affected area.

Metronidazole may cause adverse (neurological) effects.

Avoid accidental ingestion.

Do not drink, eat or smoke when administering the product.

Close the bottle immediately after use to avoid the child gaining access to the contents. Do not leave a syringe containing solution in the sight or reach of children. In order to prevent children from getting access to used syringes, keep the syringes in the original packaging after use.

In case of accidental ingestion, seek-medical advice immediately and show the package leaflet or the label to physician.

Additional warnings when administering the product into the feed:

Avoid the access of children to the dog’s medicated food. In order to prevent children from getting access to the dog’s medicated food, pour it over a part of the feed and wait until the animal has completely consumed the medicated feed, then administer the rest of the feed. Give the treatment out of the sight and reach of children. Any uneaten medicated food must be removed immediately and the bowl washed thoroughly; wear gloves and wash hands when handling the product and cleaning the contaminated food bowl.

The following adverse reactions may occur after administration of metronidazole: vomiting, hepatotoxicity and neutropenia. In very rare cases, neurological signs may occur especially after prolonged treatment with metronidazole.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Studies in laboratory animals have shown inconsistent results with regard to teratogenic/embryotoxic effects of metronidazole. Therefore, use of this product during pregnancy is not recommended. Metronidazole is excreted in milk and use during lactation is therefore not recommended.

Metronidazole may have an inhibitory effect on the degradation of other drugs in the liver, such as phenytoin, cyclosporine and warfarin.

Cimetidine may decrease the hepatic metabolism of metronidazole resulting in increased serum concentration of metronidazole.

Phenobarbital may increase hepatic metabolism of metronidazole resulting in decreased serum concentration of metronidazole.

Amounts to be administered and administration route

Oral use.

The recommended dose is 50 mg metronidazole per kg bodyweight per day (i.e. 0.4 mL per kg bodyweight), preferably given in two equally divided doses (i.e. 25 mg equivalent to 0.2 mL per kg bodyweight twice daily) for 5-7 days.

To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing and overdosing.

The dosage table is intended as a guide to dispensing the product at the volume corresponding to either 25 mg/kg for administration twice daily or 50 mg/kg for administration once daily.Examples of bodyweight (kg)Volume toadministertwice dailyfor 25mg/kgVolume toadministeronce dailyfor 50mg/kg10.4ml20.4ml0.8ml30.6ml1.2ml40.8ml1.6ml51.0ml2.0ml102.0ml4.0ml153.0ml6.0ml204.0ml8.0ml255.0ml10.0ml306.0ml12.0ml357.0ml14.0ml408.0ml16.0ml

Examples of bodyweight (kg)

Volume to

administer

twice daily

for 25mg/kg

Volume to

administer

once daily

for 50mg/kg

For doses requiring more than two filled syringes, the dosing should be twice daily in order to minimize counting and dosing errors.

The oral suspension is delivered through the package described below:

A - Shake the bottle vigorously before use.

B - Unscrew the protective overcap.

C - Insert the syringe into the upper white part of the cap (finger-grip) by pushing firmly, then, while pushing, turn the syringe to the right (clockwise) until the green smile appears.

D - Turn the bottle upside down and withdraw the prescribed volume of the product, in the upside down position.

E - Once the correct volume of the product has been drawn into the syringe, unscrew the syringe from the cap without pushing by turning it to the left (counterclockwise) until the red smile appears again, then continue to turn in order to unfasten the syringe.

The system can also be closed by turning the finger-grip manually.

F - Screw the protective overcap back on.

Administer the product by pouring it over a part of the feed or by direct administration into the animal's mouth. Wear impervious gloves when handling the product and/or administering the product into the animal's mouth.

When administered over the feed, wait until the animal has completely consumed the medicated feed, then administer the rest of the feed.

Adverse events are more likely to occur at doses and treatment durations in excess of the recommended treatment regimen. If neurological signs occur, treatment should be discontinued and the patient should be treated symptomatically.

Not applicable.

Pharmacological particulars

Pharmacotherapeutic group: Agent against protozoal disease, nitroimidazole derivative.

ATCvet code: QP51AA01.

Pharmacodynamic properties

After metronidazole has penetrated the bacteria the molecule is reduced by the sensitive bacteria (anaerobe). The metabolites that are created have a toxic effect on the bacteria through binding to the bacterial DNA. In general metronidazole is bactericidal for sensitive bacteria in concentrations equal to or a little higher than the minimum inhibiting concentration (MIC).

Minimum Inhibitory Concentrations (MICs) have been determined for metronidazole in European isolates of target bacteria, isolated from dogs with gastrointestinal disease in 2016.SpeciesMIC range (μg/ml)MIC50 (μg/ml)MIC90 (μg/ml)Clostridium spp.(C.difficile & C.perfringens)0.5 - 211

Species

MIC range (μg/ml)

MIC50 (μg/ml)

MIC90 (μg/ml)

The MICs of the collected pathogens showed mono-modal distribution profiles with good susceptibility towards metronidazole. Clinical breakpoints* for metronidazole are established for anaerobes: susceptible: ≤8 µg/ml; intermediate: 16 µg/ml; resistant: ≥32 µg/ml.

According to these breakpoints no clinical resistant strains of Clostridium spp. pathogens were observed.

*(CLSI, 2017. Performance Standards for Antimicrobial Susceptibility Testing -Twenty-Seventh Edition M100. Clinical and Laboratory Standards Institute (CLSI), Wayne, PA 19087-1898 USA)

Clinically metronidazole does not have any relevant effect on facultative anaerobe, obligate aerobe and microaerophilic bacteria.

Metronidazole is also active in protozoa. In Giardia spp. in particular, metronidazole primarily targets the trophozoites (active replication of the parasite) resulting in their death and by consequence leading to dramatic decrease in cyst shedding.

After administration of the higher dose (50 mg/day/kg of bw), the absolute bioavailability is 98 % in fasted dog. The mean maximum concentration (Cmax) was 62.4 µg/mL +/- 9.7 (mean +/- SD) in plasma and occurs between 0.25 and 4 hours after dosing (Tmax). Food was shown to decrease the oral bioavailability which remains high in fed dogs with relative F of 81% (with F fasted = 100%). Metronidazole penetrates into the tissues and bodily fluids, such as saliva, milk, vaginal secretions and semen. Metronidazole is metabolised in the liver, by side chain oxidation and glucuronide synthesis. Both metabolites and unchanged drug are eliminated in the urine (mostly) and faeces. Elimination half-life is between 3 to 5 hours.

Pharmaceutical particulars

Butylhydroxytoluene (E321)

Aluminium stearate

Stearic acid (E570)

Poultry liver powder

Triglycerides medium chain

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the immediate packaging:

- 30 ml bottle: 3 months.

- 100 ml bottle: 6 months.

Store below 30° C.

Opaque white polyethylene terephthalate bottle closed with a plastic dispenser cap.

Carton box containing a 30 ml or 100 ml bottle and a 3 ml graduated syringe.

Not all pack sizes may be marketed

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Marketing Authorisation Holder (if different from distributor)

VIRBAC

1ère avenue – 2065m – LID

06516 Carros

France

Marketing Authorisation Number

Vm 05653/4210

Date of the first authorisation or date of renewal

10 April 2018

Date of revision of the text

April 2018

Any other information

Legal category

Delivery Information

How quickly do you deliver?

Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.

What do you charge for delivery?

For UK delivery, we charge the following:

Order Total Weight Delivery
£0-£28.99 Under 2kg £2.99
2kg+ £4.99
£29-£38.99 Under 2kg Free
2kg+ £4.99
£39+ Under 2kg Free
2kg+ Free

Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products are also not always subject to the standard and/or free delivery options.

For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.

We can deliver most items to all around the world, but prices do vary. To find the exact cost of shipping your item, and to see all options available, follow these steps:

  1. Put the items you wish to order in your basket
  2. Proceed to checkout and enter your delivery address, including country
  3. Delivery information including price will automatically update to what is available to you

Delivery of aerosols

Due to restrictions aerosols can't be sent by Royal Mail. We appreciate your understanding.

Delivery of temperature controlled items

Some products, such as non-ambient items and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.

How do I cancel or return an order?

Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.

To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.

*For full details on returns, see our terms and conditions page.

Reviews

Q & A

There are currently no questions for Eradia Metronidazole Liquid for Dogs - be the first to ask one!